Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Jerry Obritsch

Obstetrics & Gynecology Bismarck, ND Medical Doctor

NPI 1093769291 CMS profile 1191444

1000 E Rosser Ave, Bismarck, ND 58501

Open in the dashboard

General payments

$22,529

102 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jerry Obritsch of Bismarck, ND is reported in the CMS Open Payments database as having received $22,529 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $162 6
2022 General $573 25
2021 General $12,079 43
2020 General $9,481 21
2019 General $235 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerry Obritsch
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Jerry Obritsch were reported at $0. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Jerry Obritsch Obstetrics & Gynecology median Middle half National median
2019 $235 $172 $62–$391 $163
2020 $9,481 $94 $36–$222 $114
2021 $12,079 $136 $42–$369 $132
2022 $573 $160 $50–$433 $149
2023 $162 $169 $56–$423 $160
2024 $0 $152 $50–$371 $164
2025 $0 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $19,109 30 payments
  2. Axonics Modulation Technologies, Inc. $1,935 13 payments
  3. Medtronic, Inc. $404 11 payments
  4. Astellas Pharma US Inc $298 15 payments
  5. Medtronic USA, Inc. $244 5 payments
  6. Coloplast Corp $155 9 payments
  7. Davol Inc. $102 1 payment
  8. CooperSurgical, Inc. $75 3 payments
  9. Daiichi Sankyo Inc. $52 3 payments
  10. Boston Scientific Corporation $36 2 payments
  11. Other $118 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,531 9 payments
  2. Travel and Lodging $2,529 7 payments
  3. Food and Beverage $2,379 85 payments
  4. Education $90 1 payment
Products named General payments · program years 2019–2023
  1. ORIAHNN $17,646 25 payments
  2. ORILISSA Womens Health $3,506 6 payments
  3. Bulkamid $1,922 12 payments
  4. Axonics r-SNM System $1,908 12 payments
  5. INTERSTIM Sacral Nerve Stimulation $404 11 payments
  6. INTERSTIM Sacral Nerve Stimulation $244 5 payments
  7. MYRBETRIQ $184 12 payments
  8. Orilissa Endocrinology $169 3 payments
  9. ARISTA AH FLEXITIP $102 1 payment
  10. Altis $101 6 payments
  11. Other $582 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

145

Median for Obstetrics & Gynecology: 65

Drug cost

$26,421

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

35.9%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 35 $19,259
Estradiol Generic 67 $6,983
Oxybutynin Chloride Er Oxybutynin Chloride Brand 17 $143
Ciprofloxacin Hcl Generic 26 $36

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$92,012

Of which drugs: $6,722

Medicare patients

467

Average age 73

Services billed

2,527

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 43%
Osteoporosis 27%
Depression 19%
Diabetes 16%
Chronic kidney disease 11%
Ischemic heart disease 8%
Cancer 8%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 12 1,400 $6,722

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record